Radium-223 Dichloride Long-term Follow-up Program

NCT ID: NCT02312960

Last Updated: 2025-03-25

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

255 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-18

Study Completion Date

2024-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients will be followed up in this study after prior treatment with BAY88-8223 / Radium-223 dichloride / Xofigo.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This long-term follow up study will enroll subjects who will be transferred from selected interventional, company sponsored trials with radium-223 dichloride (feeder trials).

The primary objectives are to define the long term safety profile of radium-223 dichloride (for up to 7 years after the last dose of radium-223 dichloride); to assess the incidence of leukemia, myelodysplastic syndrome, aplastic anemia, and primary bone cancer or any other new primary malignancy; to assess the incidence of bone fractures and bone associated events (e.g., osteoporosis); and, in subjects who receive cytotoxic chemotherapy, to assess the incidence of febrile neutropenia and hemorrhage during their chemotherapy treatment and for up to 6 months thereafter at a frequency based on local clinical practice.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasm Metastasis / Bone and Bones

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

The subjects previously enrolled in a selected radium-223 dichloride feeder trial, their treating health care professional, or caregiver will be contacted in 6-month intervals for follow up and query.

Group Type OTHER

Data Collection

Intervention Type OTHER

No study treatment will be provided in this long term follow up study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Data Collection

No study treatment will be provided in this long term follow up study.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject was previously enrolled in a selected company sponsored feeder trial, and has received at least 1 dose of radium 223 dichloride or placebo in the feeder trial

Exclusion Criteria

* Not applicable to this follow up study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bayer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Anchorage, Alaska, United States

Site Status

Tucson, Arizona, United States

Site Status

Plantation, Florida, United States

Site Status

Indianapolis, Indiana, United States

Site Status

Ashland, Kentucky, United States

Site Status

New Orleans, Louisiana, United States

Site Status

Shreveport, Louisiana, United States

Site Status

Baltimore, Maryland, United States

Site Status

Boston, Massachusetts, United States

Site Status

Detroit, Michigan, United States

Site Status

Omaha, Nebraska, United States

Site Status

Syracuse, New York, United States

Site Status

Pittsburgh, Pennsylvania, United States

Site Status

Watertown, South Dakota, United States

Site Status

Seattle, Washington, United States

Site Status

Darlinghurst, New South Wales, Australia

Site Status

Westmead, New South Wales, Australia

Site Status

Fitzroy, Victoria, Australia

Site Status

Heidelberg, Victoria, Australia

Site Status

Kortrijk, , Belgium

Site Status

Leuven, , Belgium

Site Status

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Barretos/SP, São Paulo, Brazil

Site Status

São Paulo, São Paulo, Brazil

Site Status

Toronto, Ontario, Canada

Site Status

Montreal, Quebec, Canada

Site Status

Prague, , Czechia

Site Status

Helsinki, , Finland

Site Status

Tampere, , Finland

Site Status

Bordeaux, , France

Site Status

Nantes, , France

Site Status

Nîmes, , France

Site Status

Saint-Cloud, , France

Site Status

Tours, , France

Site Status

Villejuif, , France

Site Status

Ulm, Baden-Wurttemberg, Germany

Site Status

Erlangen, Bavaria, Germany

Site Status

München, Bavaria, Germany

Site Status

Rostock, Mecklenburg-Vorpommern, Germany

Site Status

Aachen, North Rhine-Westphalia, Germany

Site Status

Mainz, Rhineland-Palatinate, Germany

Site Status

Dresden, Saxony, Germany

Site Status

Magdeburg, Saxony-Anhalt, Germany

Site Status

Jena, Thuringia, Germany

Site Status

Berlin, , Germany

Site Status

Berlin, , Germany

Site Status

Bremen, , Germany

Site Status

Chai Wan, , Hong Kong

Site Status

Afula, , Israel

Site Status

Haifa, , Israel

Site Status

Jerusalem, , Israel

Site Status

Petah Tikva, , Israel

Site Status

Ramat Gan, , Israel

Site Status

Tel Aviv, , Israel

Site Status

Zrifin, , Israel

Site Status

Forlì Cesena, Emilia-Romagna, Italy

Site Status

Modena, Emilia-Romagna, Italy

Site Status

Rome, Lazio, Italy

Site Status

Rome, Lazio, Italy

Site Status

Milan, Lombardy, Italy

Site Status

Trento, Trentino-Alto Adige, Italy

Site Status

Matsuyama, Ehime, Japan

Site Status

Sapporo, Hokkaido, Japan

Site Status

Sapporo, Hokkaido, Japan

Site Status

Kanazawa, Ishikawa-ken, Japan

Site Status

Yokohama, Kanagawa, Japan

Site Status

Yokohama, Kanagawa, Japan

Site Status

Kurashiki, Okayama-ken, Japan

Site Status

Sayama, Osaka, Japan

Site Status

Hidaka, Saitama, Japan

Site Status

Kita-Adachigun, Saitama, Japan

Site Status

Koto-ku, Tokyo, Japan

Site Status

Fukuoka, , Japan

Site Status

Kumamoto, , Japan

Site Status

Miyazaki, , Japan

Site Status

Osaka, , Japan

Site Status

Bodø, , Norway

Site Status

Oslo, , Norway

Site Status

Bialystok, , Poland

Site Status

Gliwice, , Poland

Site Status

Warsaw, , Poland

Site Status

Obninsk, , Russia

Site Status

Singapore, , Singapore

Site Status

Singapore, , Singapore

Site Status

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Daegu, , South Korea

Site Status

Incheon, , South Korea

Site Status

Seoul, , South Korea

Site Status

Seoul, , South Korea

Site Status

Badalona (Barcelona), Barcelona, Spain

Site Status

Palma de Mallorca, Illes Baleares, Spain

Site Status

A Coruña, , Spain

Site Status

Barcelona, , Spain

Site Status

Barcelona, , Spain

Site Status

Barcelona, , Spain

Site Status

Madrid, , Spain

Site Status

Madrid, , Spain

Site Status

Madrid, , Spain

Site Status

Málaga, , Spain

Site Status

Pamplona, , Spain

Site Status

Seville, , Spain

Site Status

Seville, , Spain

Site Status

Umeå, , Sweden

Site Status

Kaohsiung City, , Taiwan

Site Status

Taichung, , Taiwan

Site Status

Taipei, , Taiwan

Site Status

Taipei, , Taiwan

Site Status

Taoyuan District, , Taiwan

Site Status

Truro, Cornwall, United Kingdom

Site Status

Plymouth, Devon, United Kingdom

Site Status

Sheffield, South Yorkshire, United Kingdom

Site Status

Guildford, Surrey, United Kingdom

Site Status

Sutton, Surrey, United Kingdom

Site Status

Coventry, Warwickshire, United Kingdom

Site Status

Bristol, , United Kingdom

Site Status

Cottingham, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Belgium Brazil Canada Czechia Finland France Germany Hong Kong Israel Italy Japan Norway Poland Russia Singapore South Korea Spain Sweden Taiwan United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://www.clinicaltrialsregister.eu/ctr-search/search

Click here to find information about studies related to Bayer Healthcare products conducted in Europe

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014-002407-25

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

16996

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.